Last reviewed · How we verify
Baxter Peritoneal Dialysate
At a glance
| Generic name | Baxter Peritoneal Dialysate |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Kinetics of Extracellular Vesicles in Hemodialysis
- Pharmacokinetics of Single- and Double-dose Icodextrin (NA)
- Extracorporeal Blood Purification as a Treatment Modality for COVID-19
- Safety and Effectiveness Evaluation of Two Kinds of Peritoneal Dialysate (PHASE4)
- Optimized vs. Standard Automated Peritoneal Dialysis Regimens Study (NA)
- Strategies for Asymmetrical Triacetate Dialyzer Heparin-Free Effective Hemodialysis (PHASE2)
- Effect of Dialysis Membranes on Inflammatory and Immune Processes in Hemodialysis (NA)
- Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Baxter Peritoneal Dialysate CI brief — competitive landscape report
- Baxter Peritoneal Dialysate updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI